ARDS Clinical Trial
— GENIE-VentOfficial title:
Generating Evidence in ECMO Ventilation Strategies - A Pilot Study
Verified date | June 2024 |
Source | Duke University |
Contact | Elias H Pratt, MD |
Phone | 9192593214 |
elias.pratt[@]duke.edu | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this pilot clinical trial is to test if ICU level ventilator protocols are appropriate interventions to study differences in ventilator strategies for patients with acute respiratory failure supported by VV-ECMO. The main questions it aims to answer are: - will clinicians closely follow different ICU ventilator protocols - will different ICU ventilator protocols change the way that patients are treated. Participants will be assigned to one of two ventilator protocols based on the month that they are first started on ECMO. Researchers will compare standard lung-protective ventilation to ultra-lung protective ventilation protocols to see how this changes how the ventilator is set for patients.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | October 31, 2024 |
Est. primary completion date | July 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - All patients being treated with ECMO in the Duke University Hospital Medical ICU will be eligible Exclusion Criteria: - There are no exclusion criteria |
Country | Name | City | State |
---|---|---|---|
United States | Duke University Medical Center | Durham | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Duke University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Protocol fidelity rate | Percentage of days that a patient's ventilator settings adhere to assigned protocol | From study enrollment until removal of ECMO support or death, whichever comes first, up to 52 weeks | |
Secondary | Duration of ECMO | Total number of days a patient is supported with ECMO | From study enrollment until removal of ECMO support or death, whichever comes first, up to 52 weeks | |
Secondary | Duration of mechanical ventilation | Total number of days a patient is supported with mechanical ventilation | From study enrollment until removal of mechanical ventilatory support or death, whichever comes first, up to 52 weeks | |
Secondary | Duration of ICU admission | Total number of days a patient is cared for in the ICU | From study enrollment until hospital discharge or death, whichever comes first, up to 52 weeks | |
Secondary | Duration of Hospital admission | Total number of days patient is admitted to the hospital | From study enrollment until hospital discharge or death, whichever comes first, up to 52 weeks | |
Secondary | Survival to discharge | Whether a patient survives until hospital discharge | From study enrollment until hospital discharge or death, whichever comes first, up to 52 weeks | |
Secondary | Time to meeting criteria for ECMO weaning | Total number of days between enrollment and when a patient meets criteria for ECMO weaning | From study enrollment until meeting weaning criteria or death, whichever comes first, up to 52 weeks | |
Secondary | Time to first ECMO weaning trial | Total number of days between enrollment and when a patient first has an ECMO weaning trial | From study enrollment until first weaning trial or death, whichever comes first, up to 52 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04435613 -
Clinical and Physiological Assessment of a Nearly Ultra-protective Lung Ventilation Strategy: A Quasi-experimental Preliminary Study in ARDS Patients
|
N/A | |
Enrolling by invitation |
NCT05020210 -
Effect of Early Treatment With Sivelestat Sodium in ARDS Patients
|
||
Completed |
NCT04468971 -
REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia
|
Phase 1 | |
Completed |
NCT04505592 -
Tenecteplase in Patients With COVID-19
|
Phase 2 | |
Completed |
NCT04493242 -
Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS
|
Phase 2 | |
Withdrawn |
NCT04909879 -
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome
|
Phase 2 | |
Completed |
NCT02265198 -
Relationship of Pulmonary Contusion to Pulmonary Inflammation and Incidence of Acute Respiratory Distress Syndrome
|
N/A | |
Completed |
NCT01949272 -
Optimization of PEEP for Alveolar Recruitment in ARDS
|
N/A | |
Not yet recruiting |
NCT01668368 -
Goal Directed Mechanical Ventilation Aimed at Optimal Lung Compliance
|
N/A | |
Completed |
NCT01881061 -
Lung Sonography in Patients With Acute Respiratory Distress Syndrome in Intensive Care Unit
|
N/A | |
Completed |
NCT00808691 -
Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit
|
N/A | |
Completed |
NCT05035589 -
The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
|
||
Recruiting |
NCT04764032 -
Right Ventricular Dysfunction in Ventilated Patients With COVID-19
|
||
Completed |
NCT04556513 -
Functional Recovery From Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19: Influence of Socio-Economic Status
|
||
Recruiting |
NCT06036056 -
NMR Based Metabolomics Kinetics in ARDS Patients
|
||
Recruiting |
NCT04503876 -
Effects of End-expiratory Positive Pressure Optimization in Intubated Patients With Healthy Lung or Acute Respiratory Distress Syndrome
|
N/A | |
Recruiting |
NCT04643691 -
Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS
|
Phase 2 | |
Completed |
NCT04395911 -
Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections
|
N/A | |
Not yet recruiting |
NCT05341687 -
Prognostic Value of Respiratory System Compliance Under VV-ECMO on 180-day Mortality in COVID-19 ARDS.
|
||
Recruiting |
NCT05056090 -
Effect of Prone Positioning on Mortality in Patients With Mild to Moderate Acute Respiratory Distress Syndrome.
|
N/A |